APOA1 and inflammation: Administration of human apoA-I to allergen-challenged wild-type mice similarly, suppressed airway inflammation, AHR, dendritic cell migration to the lung, and reduced the release of IL-25, IL-33, and TSLP (thymic stromal lymphopoietin) by airway epithelial cells (Park et al., 2013).